Institute of Lipid metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, Weifang 261053, China.
Institute of Lipid metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, Weifang 261053, China; Research Center on Life Sciences and Environmental Sciences, Harbin University of Commerce, Harbin 150076, China.
Int J Biol Macromol. 2019 Jun 15;131:264-272. doi: 10.1016/j.ijbiomac.2019.03.078. Epub 2019 Mar 12.
Water extracts of the edible mushroom Cordyceps militaris possess a lipid-lowering effect. However, the types of components and how they exert this effect are not clear. In this study, two novel polysaccharides, CM1 and CMS, were isolated, and their cholesterol efflux improving capacity was investigated in vitro. The molecular weight of CM1 was approximately 700 kDa, and its main chain was consisted of (1 → 4)-β-D-Glcp and (1 → 2)-α-D-manp branched at the O-6 positions of (1 → 2,6)-α-D-manp with (1 → 2) linked-β-D-galf, (1 → 2)-α-D-manp or methyl and terminated with β-D-Galf and α-D-Manp. The molecular weight of CMS was approximately 18.2 kDa, and it was a novel (1 → 6)-β-D-Glcp linked glucan. Both CM1 and CMS significantly increased [H]-cholesterol efflux by activating the protein expression of ATP-binding cassette (ABC) G1. However, they showed no significant influence on the proteins expression of ABCA1 and scavenger receptor B type 1. Therefore, CM1 and CMS are effective water-soluble components with potential lipid-lowering activity. They may be exploited as potential candidates for dyslipidaemia-related diseases such as atherosclerosis.
蛹虫草的水提物具有降低血脂的作用。然而，其发挥作用的成分类型尚不清楚。在本研究中，分离得到了两种新型多糖 CM1 和 CMS，并在体外研究了它们的胆固醇外排改善能力。CM1 的分子量约为 700 kDa，其主链由 (1 → 4)-β-D-Glcp 和 (1 → 2)-α-D-Manp 组成，在 (1 → 2,6)-α-D-Manp 的 O-6 位支链为 (1 → 2,6)-α-D-Manp 与 (1 → 2)-β-D-galf、(1 → 2)-α-D-Manp 或甲基相连，末端为β-D-Galf 和α-D-Manp。CMS 的分子量约为 18.2 kDa，是一种新型的 (1 → 6)-β-D-Glcp 连接的葡聚糖。CM1 和 CMS 均能通过激活 ABCG1 蛋白的表达显著增加 [H]-胆固醇外排。然而，它们对 ABCA1 和清道夫受体 B 型 1 的蛋白表达没有显著影响。因此，CM1 和 CMS 是有效的水溶性成分，具有潜在的降血脂活性。它们可能被开发为动脉粥样硬化等与血脂异常相关疾病的潜在候选药物。
